人形机器人概念股爆发。 消息面上，2025年4月24日至26日，由中国电子学会主办，中国人形机器人百人会、无锡市惠山国有投资控股集团有限公司承办的首届具身智能机器人运 动会将在无锡市惠山区举办，本届运动会主要包括竞赛、嘉年华、主题会议三大系列活动，其中，竞赛、嘉年华活动场地设置在惠山区全民健身中心，4 月25日—26日采取预约形式对外开放。 此外，国际星闪联盟发布消息称，近日，由TC591全国机器人标准化技术委员会主办的"具身智能+新一代通信标准技术研讨会"成功举办。会上，TC591 全国机器人标准化技术委员会与国际星闪联盟正式签署战略合作协议，双方将围绕机器人技术与新一代无线短距通信技术的融合，推动具身智能机器人标 准化与产业化发展。 其他概念板块方面，减速器、汽车热管理、一体压铸、PEEK材料等板块盘中涨幅居前。 A股市场今天上午整体窄幅震荡。人形机器人概念股集体大涨，A股市场多只相关概念股涨停或涨幅超过10%。港股人形机器人龙头优必选盘中涨幅一度 达到12%。 随着金价的冲高回落，今天上午黄金概念股炒作退潮，多只相关概念股明显调整。 人形机器人概念股集体大涨 A股市场今天上午整体窄幅震荡。截至中午收盘， ...

Core Viewpoint - The A-share market experienced a narrow fluctuation in the morning, with humanoid robot concept stocks collectively surging, while gold concept stocks faced a decline due to the fluctuation in gold prices [1][7]. Market Overview - The A-share market showed slight gains by noon, with the Shanghai Composite Index up 0.04%, the Shenzhen Component Index up 0.70%, and the ChiNext Index up 1.02%. Over 3,000 stocks in the market rose [3]. - Humanoid robot concept stocks saw significant increases, with the sector rising over 4% during the session. Notable performers included Zhaomin Technology with a 20% limit up, Lida Bearings up over 17%, and Nanshan Zhishang up over 14% [4][5]. Sector Performance - In terms of industry sectors, general machinery, automotive, engineering machinery, and components led the gains, while commercial retail, agriculture, forestry, animal husbandry, non-ferrous metals, and aviation sectors faced declines [4]. - Other concept sectors such as reducers, automotive thermal management, die-casting, and PEEK materials also showed strong performance [7]. Company Earnings Reports - Companies are currently disclosing their Q1 2025 earnings reports, with several experiencing significant stock price increases. For instance, Zhejiang Shibao reported a 45.47% year-on-year increase in revenue to RMB 718 million, with net profit rising by 123.77% to RMB 48.73 million [9][10]. - Jian Erkang also reported a 13.69% increase in revenue to RMB 241 million, with net profit up 15.42% to RMB 28.81 million [10]. - Hechang Polymer reported a 32.23% increase in revenue to RMB 435 million [12]. Hong Kong Market Performance - The Hong Kong market saw a significant rise, with the Hang Seng Index up over 2%. Key stocks such as Xiaomi Group-W, Alibaba-W, WuXi Biologics, and BYD saw gains exceeding 4% [14]. - The Hang Seng Technology Index rose over 3%, with Horizon Robotics-W experiencing a peak increase of over 13% [15]. - In the Hong Kong Stock Connect, Jingcheng Electromechanical Holdings surged over 18%, while Yum China rose over 15%. The humanoid robot leader, UBTECH, saw a peak increase of 12% [16].

4月23日，"可月月评估分红"的港股红利ETF基金（513820）小幅震荡，当前涨0.74%，冲击三连阳。据公开资料，港股红利ETF基金（513820）已发布连续 第10月分红公告。 南向资金持续抢筹港股，哑铃策略"科技+红利"为主要配置方向。当前港股红利资产配置价值突出： 4月22日，港股红利ETF基金（513820）连续第10个月发布分红公告，本次分红每10份派0.01元，纳入此次分红在内，港股红利ETF基金（513820）每10份已 累计分红0.29元。本次分红有三大重要时点值得关注： 1、分红权益登记日：4月24日，该日收盘前持有的基金份额可以参与本次分红。 2、除息日：4月25日，当日基金单位净值开盘前会有小幅下调，不必惊慌，这是扣除每份基金分红金额，意味着离分红到账又进一步。 3、现金红利发放日：4月30日，投资者在当日即可领取现金红利，落袋为安！ 公开资料显示，自2024年7月以来，"月月评估分红"的港股红利ETF基金（513820）连续10个月分红到账日，均为每个月月底！ | 分红 | 权益登记日 | 除息日 | 现金红利发放日 | 分红方案(单位 /10份基金份额 | | --- | --- ...

金融界2025年4月22日消息，中欧医疗创新股票A(006228) 最新净值1.1989元，增长4.41%。该基金近1个 月收益率-0.29%，同类排名82|506；近3个月收益率18.96%，同类排名7|504；今年来收益率15.30%，同 类排名14|502。 中欧医疗创新股票A股票持仓前十占比合计75.62%，分别为：药明合联（10.35%）、科伦博泰生 （10.15%）、药明生物（9.82%）、药明康德（9.60%）、康方生物（7.89%）、康龙化成（7.01%）、 恒瑞医药（6.20%）、凯莱英（5.87%）、百利天恒（4.70%）、泰格医药（4.03%）。 公开资料显示，中欧医疗创新股票A基金成立于2019年2月28日，截至2025年3月31日，中欧医疗创新股 票A规模46.75亿元，基金经理为葛兰。 来源：金融界 简历显示：葛兰女士:中国籍。美国西北大学生物医学工程专业博士。历任国金证券股份有限公司研究 所研究员,民生加银基金管理有限公司研究员。2014年10月加入中欧基金管理有限公司,曾任研究员、中 欧明睿新起点灵活配置混合型证券投资基金基金经理(2015年1月29日起至2016年4月22日) ...

截至收盘，南向资金净买额逾213亿港元。恒生科技指数涨0.24%，医药、贵金属板块走强，石药集团 涨超8%，药明生物涨超5%，紫金矿业涨超4%；小米集团涨超5%；京东跌超6%，美团跌超4%。 ...

港股午评：恒生指数跌0.04% 黄金、创新药板块领涨 智通财经4月22日电，港股午间收盘，恒生指数跌0.04%，恒生科技指数跌0.5%。黄金、创新药板块领 涨，赤峰黄金、山东黄金涨超10%；歌礼制药-B涨近20%，药明生物涨超3%。 ...

Group 1 - The Hong Kong pharmaceutical ETF (513700.SH) increased by 3.14%, with major constituents such as Xintai Medical rising by 60%, Meizhong Jiahe by 26%, and Nuocheng Jianhua by 13% [1] - Yuan Da Pharmaceutical announced a milestone breakthrough in its clinical research for the innovative radioactive nuclide-conjugated drug (RDC) GPN02006 for diagnosing hepatocellular carcinoma (HCC), achieving high-quality imaging within 30 minutes of administration [1] - GPN02006 provides strong molecular imaging evidence for personalized treatment plans, addressing the clinical need for rapid diagnosis of HCC and improving early diagnosis rates and monitoring of recurrence and metastasis [1] Group 2 - Guojin Securities believes that innovative drugs in the Hong Kong stock market will be a key investment theme in 2025, driven by AI enabling shorter R&D cycles, reduced costs, and improved efficiency [2] - The recovery of investment and financing activities in the global pharmaceutical industry is beneficial for improving cash flow for innovative drug companies [2] - Anticipation of fiscal stimulus, including the imminent release of the "Class B Directory," may catalyze valuation and sentiment recovery in the sector [2]

Group 1 - China Unicom (00762.HK) reported Q1 2025 revenue of RMB 103.35 billion, a year-on-year increase of 3.9%, with net profit of RMB 5.93 billion, up 5.6% [1] - Tongcheng Travel (00780.HK) announced an agreement to acquire Wanda Hotel Management (Hong Kong) Co., Ltd. for approximately RMB 2.49 billion [1] - China Tower (00788.HK) achieved Q1 2025 revenue of RMB 24.771 billion, a year-on-year growth of 3.3%, with profit attributable to shareholders of RMB 3.024 billion, up 8.6% [1] - SF Holding (06936.HK) reported combined revenue of RMB 23.661 billion from express logistics, supply chain, and international business in March, reflecting a year-on-year increase of 9.63% [1] Group 2 - Zhaojin Mining (01818.HK) recorded Q1 revenue of RMB 3.041 billion, a year-on-year increase of 53.5%, with net profit attributable to shareholders of RMB 659 million, up 197.76%, and basic earnings per share of RMB 0.17 [2] - Yanzhou Coal Mining (01171.HK) reported Q1 self-produced coal sales of 30.6 million tons, a year-on-year decrease of 1.71% [2]

Group 1 - The core index, the CESHKB, closed flat with a trading volume of 0.0 billion, reflecting a recent decline of 6.54% over the past month, but an increase of 26.60% over the last three months and a year-to-date rise of 21.09% [1] - The CESHKB index is compiled by China Securities Index Co., Ltd. under the commission of China Securities Trading Service Co., Ltd., aiming to reflect the overall performance of biotechnology companies listed in Hong Kong [1] - The base date for the index is December 12, 2014, with a base point of 2000.0 [1] Group 2 - The top ten holdings of the CESHKB index include: CanSino Biologics (11.12%), Innovent Biologics (10.75%), BeiGene (10.09%), WuXi Biologics (9.6%), China National Pharmaceutical Group (9.38%), Zai Lab (5.61%), 3SBio (5.2%), WuXi AppTec (4.56%), Kelun-Biotech (4.25%), and Genscript Biotech (3.54%) [1] - The index's holdings are entirely composed of companies listed on the Hong Kong Stock Exchange, with the biotechnology sector representing 60.67%, pharmaceutical and biotechnology services at 22.64%, chemical drugs at 13.14%, and medical devices at 3.55% [2]

Core Points - The China-Hong Kong-US Technology Index has shown a decline of 14.62% over the past month, 3.85% over the past three months, and 3.32% year-to-date [1] - The index is composed of high liquidity and high market capitalization technology companies listed in Hong Kong and the US, calculated using an equal-weighted method [1] - The index's top ten holdings include companies such as SMIC (3.61%), BYD (3.23%), and Alibaba (2.55%) [1] Market Composition - The Nasdaq Global Select Market accounts for 40.10% of the index, followed by the Hong Kong Stock Exchange at 36.04% and the New York Stock Exchange at 22.41% [2] - The industry breakdown of the index shows that Information Technology comprises 38.88%, Consumer Discretionary 20.37%, and Healthcare 14.75% [2] Index Adjustment Mechanism - The index samples are adjusted biannually, with changes implemented on the next trading day after the second Friday of June and December [2] - New technology companies that rank in the top five by market capitalization in their respective regions will be quickly included in the index after their eleventh trading day [2]